v3.22.2.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Operating Expenses        
Research and development expenses $ 3,136,838 $ 1,722,364 $ 8,319,907 $ 4,806,845
Acquisition of in-process research and development 50,953 566,583
General and administrative expenses 2,920,280 1,338,113 6,137,674 3,391,105
Operating Loss (6,057,118) (3,111,430) (14,457,581) (8,764,533)
Other Income (Expense)        
Forgiveness of PPP loan and related accrued interest 163,771
Interest income, net 36,708 1,771 45,672 8,163
Net Operating Loss Before Income Tax Benefit (6,020,410) (3,109,659) (14,411,909) (8,592,599)
Income Tax Benefit 122,442 348,859
Net Loss $ (6,020,410) $ (2,987,217) $ (14,411,909) $ (8,243,740)
Net Loss per Common Share - Basic and Diluted $ (0.37) $ (0.19) $ (0.90) $ (0.54)
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic and Diluted 16,200,222 15,531,442 15,991,653 15,177,306

Source